Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

Not Applicable

Completed

• Conditions: Healthy

• Registration Number: NCT06774807
• Lead Sponsor: University of Copenhagen

Brief Summary

This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.

Detailed Description

Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.

Study Timeline

• Study Start: 2024-05-01
• Primary Completion: 2024-09-01
• Study Completion: 2024-09-07
• Study First Submitted: 2025-01-07
• Study First Submitted QC: 2025-01-07
• Study First Posted: 2025-01-14
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-29
• Last Update Posted: 2025-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Age 18-70 years
• BMI 19-28 kg/m2

Exclusion Criteria

• Chronic illness that affects the cardiovascular system or gastrointestinal tract
• Treatment with medicine or supplements that cannot be paused for 12 hours
• Intake of above 14 alcoholic drinks per week or substance abuse
• Liver enzymes (ALAT) above 2 times normal values
• Decreased kidney function (eGFR below 90 or creatinine levels over reference value)
• Low blood percentage (hemoglobin below reference value)
• Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
SMA blood flow	85 minutes	Blood flow in the superior mesenteric artery

Secondary Outcome Measures

Name	Time	Method
PVblood flow	85 minutes	Blood flow in the portal vein

Trial Locations

Locations (1)

Rigshospitalet; 🇩🇰 Copenhagen, Denmark